一种用于下一代抗菌药物的CRISPR设计。

相似文献

1

A CRISPR design for next-generation antimicrobials.

Genome Biol. 2014 Nov 8;15(11):516. doi: 10.1186/s13059-014-0516-x.

2

Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.

Nat Biotechnol. 2014 Nov;32(11):1141-5. doi: 10.1038/nbt.3011. Epub 2014 Sep 21.

3

RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.

Mol Cell. 2018 Sep 6;71(5):791-801.e3. doi: 10.1016/j.molcel.2018.07.013. Epub 2018 Aug 16.

4

Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.

Nat Biotechnol. 2014 Nov;32(11):1146-50. doi: 10.1038/nbt.3043. Epub 2014 Oct 5.

5

Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance.

PLoS One. 2023 Sep 12;18(9):e0291520. doi: 10.1371/journal.pone.0291520. eCollection 2023.

6

Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs.

Methods Enzymol. 2014;546:21-45. doi: 10.1016/B978-0-12-801185-0.00002-7.

7

Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28.

Mol Cell. 2017 Feb 16;65(4):618-630.e7. doi: 10.1016/j.molcel.2016.12.023. Epub 2017 Jan 5.

8

Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.

J Mol Biol. 2019 Jan 4;431(1):66-87. doi: 10.1016/j.jmb.2018.06.029. Epub 2018 Jun 22.

9

Resources for the design of CRISPR gene editing experiments.

Genome Biol. 2015 Nov 27;16:260. doi: 10.1186/s13059-015-0823-x.

10

Efficient inter-species conjugative transfer of a CRISPR nuclease for targeted bacterial killing.

Nat Commun. 2019 Oct 4;10(1):4544. doi: 10.1038/s41467-019-12448-3.

引用本文的文献

1

CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions.

Infect Drug Resist. 2024 Nov 26;17:5229-5245. doi: 10.2147/IDR.S494327. eCollection 2024.

2

Role of CRISPR-Cas systems in periodontal disease pathogenesis and potential for periodontal therapy: A review.

Mol Oral Microbiol. 2025 Feb;40(1):1-16. doi: 10.1111/omi.12483. Epub 2024 Sep 3.

3

CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.

ACS Infect Dis. 2023 Jul 14;9(7):1283-1302. doi: 10.1021/acsinfecdis.2c00649. Epub 2023 Jun 22.

4

Future pandemics might be caused by bacteria and not viruses: Recent advances in medical preventive practice.

Int J Health Sci (Qassim). 2022 May-Jun;16(3):1-3.

5

CRISPR-Cas Technology: Emerging Applications in Clinical Microbiology and Infectious Diseases.

Pharmaceuticals (Basel). 2021 Nov 17;14(11):1171. doi: 10.3390/ph14111171.

6

Targeting of Uropathogenic Escherichia coli papG gene using CRISPR-dot nanocomplex reduced virulence of UPEC.

Sci Rep. 2021 Sep 7;11(1):17801. doi: 10.1038/s41598-021-97224-4.

7

CRISPR-based antimicrobials to obstruct antibiotic-resistant and pathogenic bacteria.

PLoS Pathog. 2021 Jul 8;17(7):e1009672. doi: 10.1371/journal.ppat.1009672. eCollection 2021 Jul.

8

Cross-species RNA-seq for deciphering host-microbe interactions.

Nat Rev Genet. 2021 Jun;22(6):361-378. doi: 10.1038/s41576-021-00326-y. Epub 2021 Feb 17.

9

Immunotherapy and vaccination against infectious diseases.

Wien Klin Wochenschr. 2021 Jul;133(13-14):714-720. doi: 10.1007/s00508-020-01746-2. Epub 2020 Dec 16.

10

Prospects for the Use of New Technologies to Combat Multidrug-Resistant Bacteria.

Front Pharmacol. 2019 Jun 21;10:692. doi: 10.3389/fphar.2019.00692. eCollection 2019.

本文引用的文献

1

Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials.

Nat Biotechnol. 2014 Nov;32(11):1146-50. doi: 10.1038/nbt.3043. Epub 2014 Oct 5.

2

Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases.

Nat Biotechnol. 2014 Nov;32(11):1141-5. doi: 10.1038/nbt.3011. Epub 2014 Sep 21.

3

Development and applications of CRISPR-Cas9 for genome engineering.

Cell. 2014 Jun 5;157(6):1262-1278. doi: 10.1016/j.cell.2014.05.010.

4

Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems.

mBio. 2014 Jan 28;5(1):e00928-13. doi: 10.1128/mBio.00928-13.

5

Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape bacterial genomes and expel or remodel pathogenicity islands.

PLoS Genet. 2013 Apr;9(4):e1003454. doi: 10.1371/journal.pgen.1003454. Epub 2013 Apr 18.

6

CRISPR-mediated adaptive immune systems in bacteria and archaea.

Annu Rev Biochem. 2013;82:237-66. doi: 10.1146/annurev-biochem-072911-172315. Epub 2013 Mar 11.

7

CRISPR interference can prevent natural transformation and virulence acquisition during in vivo bacterial infection.

Cell Host Microbe. 2012 Aug 16;12(2):177-86. doi: 10.1016/j.chom.2012.06.003.

8

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.

Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829. Epub 2012 Jun 28.

9

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA.

Nature. 2010 Nov 4;468(7320):67-71. doi: 10.1038/nature09523.

10

CRISPR provides acquired resistance against viruses in prokaryotes.

Science. 2007 Mar 23;315(5819):1709-12. doi: 10.1126/science.1138140.

A CRISPR design for next-generation antimicrobials.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

一种用于下一代抗菌药物的CRISPR设计。

A CRISPR design for next-generation antimicrobials.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献